硼中子俘获治疗在头颈癌中的当前作用:4年临床经验启示
该研究回顾性分析了2020年6月至2024年5月期间接受初始硼中子俘获治疗(BNCT)的285例头颈癌患者,中位随访至少1个月。2年局部控制率、无进展生存率和总生存率分别为41.5%、26.4%和59.2%,客观缓解率为80.4%,≥3级晚期不良事件2年累积发生率为14.0%,5级不良事件发生率为2.1%。结论建议在无其他有效治疗方案的早期疾病阶段实施BNCT。
要点
- 2年局部控制率41.5%、无进展生存率26.4%、总生存率59.2%。
- 客观缓解率80.4%,完全缓解率47.0%,部分缓解率33.3%。
- 鳞状细胞癌患者总生存显著劣于非鳞状细胞癌患者。
核心结论
- BNCT应在无其他有效治疗方案的早期疾病阶段实施,需进一步研究确定影响疗效和安全性的因素以优化多模式治疗策略。
研究设计与样本
- 回顾性分析2020年6月至2024年5月期间接受初始BNCT且随访数据≥1个月的285例头颈癌患者,主要终点为局部控制,次要终点包括无进展生存、总生存、治疗反应和≥3级不良事件。
主要发现
- 2年局部控制率、无进展生存率和总生存率分别为41.5%、26.4%和59.2%。
- 完全缓解率、部分缓解率和客观缓解率分别为47.0%、33.3%和80.4%。
- ≥3级晚期不良事件2年累积发生率为14.0%,5级不良事件发生率为2.1%。
- 不同组织学类型亚组间局部控制和无进展生存无显著差异,但鳞状细胞癌患者总生存显著劣于非鳞状细胞癌患者。
- 照射时TNM分期早与局部控制改善显著相关。
临床怎么用
- 对于无其他有效治疗方案的早期头颈癌患者,可考虑实施BNCT。
- 鳞状细胞癌患者接受BNCT时需关注其总生存较差的风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Boron neutron capture therapy (BNCT) was approved in Japan in June 2020 as a curative option for unresectable, locally advanced, or recurrent head and neck cancers. Relevantly, its efficacy and safety in clinical practice should be regularly monitored, particularly regarding its optimal positioning. Therefore, to advance its clinical application, we assessed clinical data on BNCT for head and neck cancers. METHODS: We retrospectively analyzed 285 patients who received initial BNCT between June 2020 and May 2024 with available ≥1 month follow-up data. The primary endpoint was local control (LC); secondary endpoints included progression-free survival (PFS), overall survival (OS), treatment response, and grade ≥ 3 adverse events. RESULTS: The 2-year LC, PFS, and OS rates were 41.5%, 26.4%, and 59.2%, respectively. The complete response (CR), partial response (PR), and objective response (CR + PR) rates were 47.0%, 33.3%, and 80.4%, respectively. The cumulative incidence of grade ≥ 3 late adverse events was 14.0% at 2 years, with grade 5 adverse events occurring in 2.1% of patients. No significant differences were observed in LC or PFS among histological type subgroups; however, OS was significantly worse in patients with squamous cell carcinoma (SqCC) than in patients with non-SqCC. Regarding TNM stage at irradiation, radiation therapy at an early disease stage was significantly associated with improved LC. CONCLUSIONS: BNCT should be administered during the early disease stages when no other effective treatment options are available. Further studies should determine the factors contributing to treatment efficacy and safety, thereby optimizing multimodal treatment strategies involving BNCT.
引用
- Takeno S, Yoshino Y, Aihara T, et al. Current role of boron neutron capture therapy in head and neck cancer: insights from 4 years of clinical experience. Clin Transl Radiat Oncol. 2026. PMID: 42898130. doi:10.1016/j.ctro.2026.101316
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。